Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma

NEW YORK, August 11, 2017 /PRNewswire/ --

If you want a Stock Review on IMGN, INCY, INFI, or JAZZ then come over to and sign up for your free customized report today. is currently focused on the global Biotech market, which is mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases. Equities in this morning's lineup are: ImmunoGen Inc. (NASDAQ: IMGN), Incyte Corp. (NASDAQ: INCY), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Access's complimentary reports for today's stocks line-up at: ImmunoGen 

Shares in Waltham, Massachusetts headquartered ImmunoGen Inc. dropped 5.57%, ending Thursday's trading session at $5.42. The stock recorded a trading volume of 3.21 million shares, which was higher than its three months average volume of 3.07 million shares. The Company's shares have surged 36.52% over the last three months and 165.69% on an YTD basis. The stock is trading 48.31% above its 200-day moving average. Moreover, shares of ImmunoGen, which develops targeted anticancer therapeutics, have a Relative Strength Index (RSI) of 43.92.

On July 28th, 2017, ImmunoGen reported financial results for the quarter ended June 30th, 2017. Revenues for the quarter were $39.0 million, operating expenses were $44.2 million, and net loss was $8.9 million. As of June 30th, 2017, the Company had approximately $150.3 million in cash and cash equivalents, and had $100.0 million of convertible debt outstanding. Visit us today and access your complete report on IMGN for free at: Incyte 

Wilmington, Delaware headquartered Incyte Corp.'s stock plummeted 6.12%, closing the day at $122.12 with a total trading volume of 1.38 million shares. The Company's shares have advanced 4.89% in the previous three months and 21.79% since the start of this year. The stock is trading 0.79% above its 200-day moving average. Additionally, shares of Incyte, which focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the US and internationally, have an RSI of 40.65.

On July 25th, 2017, Incyte and Eli Lilly announced that a resubmission to the US Food and Drug Administration (FDA) for the New Drug Application for baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis, will be delayed beyond 2017. The companies will be further discussing the path forward with the agency and evaluating options for resubmission, including the potential for an additional clinical study, as requested by the FDA. The complimentary research report on INCY can be accessed at: Infinity Pharma 

On Thursday, shares in Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc. recorded a trading volume of 343,277 shares. The stock ended the day 1.68% lower at $1.17. The Company's shares are trading below their 50-day moving average by 25.81%. Furthermore, shares of Infinity Pharma, which develops medicines for patients with difficult-to-treat diseases in the US, have an RSI of 32.88.

On July 27th, 2017, Infinity Pharma announced that it has amended its license agreement with Takeda Oncology for IPI-549, its potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Under the amended agreement, the Company will no longer have an obligation to pay Takeda future royalties on worldwide net sales of selective inhibitors of PI3K-gamma, including IPI-549. Register for free on and download the research report on INFI at: Jazz Pharma 

Dublin, Ireland headquartered Jazz Pharmaceuticals PLC's stock rose 0.53%, finishing yesterday's session at $143.66. A total volume of 579,095 shares was traded, which was above their three months average volume of 469,610 shares. The Company's shares have advanced 31.76% on an YTD basis. The stock is trading above its 200-day moving average by 6.02%. Additionally, shares of Jazz Pharma, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have an RSI of 32.26.

On August 03rd, 2017, Jazz Pharma announced that the US FDA has approved Vyxeos(TM) (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of Acute Myeloid Leukemia, a rapidly progressing and life-threatening blood cancer. Vyxeos is indicated for the treatment of adults with newly-diagnosed t-AML or AML-MRC. Get free access to your research report on JAZZ at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA